Legend Biotech

Price Controls And Competitive Risks Will Challenge Cell Therapy Recovery

AnalystLowTarget

Not Invested

Consensus Narrative from 18 Analysts

Published

26 Aug 25

Updated

26 Aug 25

AnalystLowTarget's Fair Value

US$54.00

35.0% undervalued

26 Aug

US$35.08

-38.5%

-4.0%

-38.5%

-4.0%

Author's Valuation

US$54.0

35.0% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$54.0

35.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

26.84%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$251.92m

Earnings '28

48.80x

PE Ratio '28

US$12.29b

Market Cap '28

US$12.29b

Market Cap '28

187.97m

No. shares '28

US$65.40

Share Price '28

US$65.40 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$53.72

Fair Value '25